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ABSTRACT
SIMPSON, A. J., L. M. ROMER, and P. KIPPELEN. Self-reported Symptoms after Induced and Inhibited Bronchoconstriction in
Athletes. Med. Sci. Sports Exerc., Vol. 47, No. 10, pp. 2005–2013, 2015. Purpose: A change in the perception of respiratory symptoms
after treatment with inhaled beta2 agonists is often used to aid diagnosis of exercise-induced bronchoconstriction (EIB). Our aim was to test
the association between subjective ratings of respiratory symptoms and changes in airway caliber after induced and inhibited broncho-
constriction in athletes with EIB.Methods: Eighty-five athletes with diagnosed or suspected EIB performed a eucapnic voluntary hyperpnea
(EVH) challenge with dry air. Of the 45 athletes with hyperpnea-induced bronchoconstriction [i.e., post-EVH fall in forced expiratory
volume in 1 s (FEV1) Q10%, EVH
j], 36 were randomized in a double-blind, placebo-controlled, crossover study. Terbutaline (0.5 mg) or
placebo was administered by inhalation 15 min before EVH. Spirometry (for FEV1) was performed before and after EVH, and respiratory
symptoms were recorded 15 min after EVH on visual analog scales. Results: Terbutaline inhibited bronchoconstriction (i.e., maximal fall in
FEV1 G10% after EVH) in 83% of the EVH-positive athletes, with an average degree of bronchoprotection of 53% (95% confidence interval
[CI], 45% to 62%). Terbutaline reduced group mean symptom scores (P G 0.01), but the degree of bronchoprotection did not correlate with
individual differences in symptom scores between terbutaline and placebo. Of the 29 athletes who had less than 10% FEV1 fall after EVH in
the terbutaline condition, almost half (48%) rated at least one respiratory symptom higher under terbutaline, and more than one quarter (28%)
had a higher total symptom score under terbutaline.Conclusion: Self-reports of respiratory symptoms in conditions of induced and inhibited
bronchoconstriction do not correlate with changes in airway caliber in athletes with EIB. Therefore, subjective ratings of respiratory
symptoms after treatment with inhaled beta2 agonists should not be used as the sole diagnostic tool for EIB in athletes. Key Words:
EXERCISE-INDUCED BRONCHOCONSTRICTION, ASTHMA, INHALED BETA2 AGONIST, TERBUTALINE, SPORT
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thletes frequently report respiratory symptoms on ex-
ertion, with almost a third of recreational roadrunners
(29) and more than 70% of elite athletes—whether
summer athletes (17), swimmers (35), or winter athletes (7)—
reporting cough, wheeze, breathlessness, chest tightness, and/
or mucus hypersecretion during or shortly after exercise. In a
significant number of athletes, respiratory symptoms may arise
from local release of inflammatory mediators (such as pros-
taglandins or leukotrienes) after dehydration of the airway
surface lining in response to exercise hyperpnea and from ensuing
narrowing of the airways (3). High prevalence of exercise-induced
bronchoconstriction (EIB) has been reported in regular exer-
cisers (21,23) and elite athletes (9). In approximately half
of athletes, however, EIB does not explain the occurrence of
symptoms (31). Hence, self-reported respiratory symptoms
have been shown to have poor sensitivity and poor specificity
for the diagnosis of EIB in athletes (17,31).
Despite the poor predictive value of respiratory symptoms
in the diagnosis of EIB in athletes, health care providers rely
heavily on symptoms for diagnosis (18,26). A change in the
perception of respiratory symptoms after treatment with
bronchodilator drugs, such as inhaled beta2 agonists, is used
routinely to aid diagnosis of EIB. In the USA, most (78%) of
family physicians and almost half of pulmonologists start
empiric treatment with short-acting bronchodilators before
exercise when EIB is suspected in an athlete (26). This
symptom-based approach may explain the high rate of un-
derdiagnosis and overdiagnosis of EIB reported in recrea-
tional (21,23) and elite athletes (4,12,24), and may contribute
to inappropriate use of asthma medication (1).
The primary aim of the current study was to test the asso-
ciation between subjective ratings of respiratory symptoms
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and changes in airway caliber after induced and inhibited
bronchoconstriction in athletes with EIB. Our primary hypoth-
esis was that perception scores for respiratory symptoms would
not correlate with the change in airway caliber induced by dry
air hyperpnea with and without prophylactic administration of
a single therapeutic dose of the inhaled bronchodilator terbuta-
line. The secondary aim was to determine whether subjective
ratings of respiratory symptoms after bronchial provocation
challenge could differentiate athletes with EIB and those with-
out EIB. Our secondary hypothesis was that self-report of re-
spiratory symptoms would neither identify nor exclude the
presence of hyperpnea-induced bronchoconstriction in athletes.
MATERIALS AND METHODS
Participants
Participants were recruited from the Brunel University
community and from local sports clubs. Eligible participants
were male or female athletes, age 18 to 55 yr, trained regu-
larly, and had a prior medical diagnosis of asthma and/or EIB
or had suspected EIB (i.e., self-report of respiratory symptoms
on exertion). Exclusion criteria were: baseline forced expira-
tory volume in 1 s (FEV1) 65% or less than predicted, chest
or upper respiratory tract infection in the 4 wk before test-
ing; smoking; pregnancy; current ‘‘severe persistent asthma’’
[according to GINA classification (16)]; anaphylaxis; and
any medical condition other than asthma or EIB.
The participants were requested to refrain from caffeine- or
alcohol-containing drinks on the day of the study, to refrain
from exercise within 4 h, and to avoid use of asthma medica-
tion for an appropriate period, i.e., 8 h for short-acting inhaled
beta2 agonists, 12 h for inhaled corticosteroids and ipratropium
bromide, 24 h for inhaled long-acting beta2 agonists (alone or
in combination with an inhaled corticosteroid), 72 h for anti-
histamines, and 4 d for leukotriene receptor antagonists.
All participants provided written informed consent ahead of
enrolment. Ethical approval was granted by the National Health
Service Research Ethics Committee (ref #10/H0716/30).
Study Design
The study included two parts. Part 1 served as the screening
visit (i.e., identification of athletes with EIB) and helped to
address our secondary aim, based on the cross-sectional
analysis of self-reported respiratory symptoms in athletes
with and without EIB. Part 2 was designed to address our
primary aim; it used a randomized, double-blind, placebo-
controlled crossover design, with analysis of self-reported
respiratory symptoms and airway caliber (via spirometry)
after bronchial provocation with dry air in athletes with EIB
premedicated with a short-acting beta2 agonist or placebo.
The study was conducted at the Centre for Sports Medicine
and Human Performance, Brunel University London, UK,
from November 2010 to October 2012.
Part 1. Eligible participants performed a standardized
eucapnic voluntary hyperpnea (EVH) test (2). Briefly, the
participants were asked to breathe for 8 min while connected
to a commercially available system (EucapSys, SMTEC,
Nyon, Switzerland) that delivered a dry gas mixture of
21% O2, 5% CO2, and balance N2 and provided the partic-
ipants with visual feedback of their ventilation. Target ven-
tilation was set at 30 times baseline FEV1 [i.e., 85% of
predicted maximal voluntary ventilation (MVV)]; the mini-
mum threshold was set at 60% MVV (2). Before, and at
regular intervals after EVH (2, 5, 10, 15, and 20 min), forced
vital capacity maneuvers were performed on a spirometer
(MicroLoop, Micromedical, Kent, UK) according to ATS/
ERS recommendations (22). Predicted values were calcu-
lated using the equations of Quanjer et al. (27). Participants
who complained about severe respiratory distress after EVH
were administered 400 Kg salbutamol via a spacer. All of the
other participants recovered spontaneously. At 15 min after
EVH, or immediately before drug administration (for those
with severe respiratory distress), the participants rated their
respiratory symptoms (i.e., cough, wheeze, chest tightness,
and mucus secretion) on visual analog scales.
Part 2. Part of the methodology and spirometry data
collected for the second part of this study has been published
elsewhere to address a separate research question (33).
Athletes with confirmed EIB (i.e., maximum fall in FEV1
Q10% after EVH in Part 1) were invited to return for Part 2.
Briefly, an EVH test was performed at the same time of day
(between 8:00 and 11:00 a.m.) on 2 d separated by at least
72 h. The order of treatment was randomly assigned with
the use of a computerized random number generator. The
participants and the experimenters were blinded to the order
of the treatment conditions. A single therapeutic dose of
0.5 mg of the beta2 agonist terbutaline (Bricanyl Turbohaler,
Astra Zeneca, London, UK) or a placebo was administered
by inhalation 15 min before EVH. An empty demonstra-
tion Turbohaler was used for administration of the placebo.
On both occasions, the participants were instructed to take
one deep, hard inhalation and to hold their breath for 10 s.
As for Part 1, the target ventilation for the EVH challenge
was set at 85% predicted MVV. To standardize for the
level of ventilation between conditions, the average venti-
lation achieved during the EVH challenge at the first visit
was used as the target ventilation for the EVH challenge
at the second visit. Recovery from the EVH test was spon-
taneous for all participants. Forced vital capacity maneuvers
were performed at rest (before treatment administration),
10 min after treatment (taken as baseline), and at 2, 5, 10, 15,
20, 30, and 60 min recovery. Respiratory symptoms were
recorded on visual analog scales at 15-min recovery.
Outcome Measures
The primary outcome measures were the maximum fall in
FEV1 after EVH and the respiratory symptom scores. Forced
expiratory volume in 1 s was recorded at least three times
before EVH and in duplicate after EVH. In cases where ma-
neuvers were not reproducible (i.e., FEV1 varied by 9150 mL),
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additional maneuvers were conducted (up to eight before EVH
and up to four after EVH). The best reproducible FEV1 was
kept for analysis. The maximum fall in FEV1 after EVH was
calculated as the difference between baseline FEV1 minus the
lowest postchallenge FEV1, divided by baseline FEV1, and
expressed as a percentage. The degree of bronchoprotection
afforded by terbutaline was calculated by subtracting the
maximum fall in FEV1 on the drug treatment day from the
maximum fall in FEV1 on the placebo day, and expressing it
as a percentage of the placebo. Bronchoconstriction was
considered to be inhibited when the maximum FEV1 fall after
EVH in the terbutaline condition was less than 10% from
baseline. Respiratory symptoms were assessed via a 10-cm
visual analog scale (with ‘‘0’’ signifying completely free of
the symptom and ‘‘10’’ the worst participants could envisage
feeling) and were measured to the nearest 0.1 cm. The par-
ticipants were instructed to rate their symptoms as the worst
they felt during the EVH challenge or in the first 15 min after
completion of the challenge. Cough, wheeze, chest tightness,
and mucus secretion were individually recorded. For each
participant, an overall respiratory symptom score was com-
puted by adding scores of the four individual symptoms.
Delta values were calculated as the difference between symp-
tom scores under terbutaline minus symptom scores under
placebo (with a negative delta value indicating an improved
respiratory symptom score under terbutaline).
Statistical Analyses
A Shapiro–Wilk test was conducted on all study vari-
ables to identify the ones following a normal distribution.
For Part 1, participants with a positive and negative response
to EVH (using a 10% fall in FEV1 as threshold value) were
compared for baseline characteristics, maximum fall in
FEV1 after EVH, and respiratory symptom scores using
unpaired t-tests, the Mann–Whitney U, or chi-square as ap-
propriate. Pearson or Spearman correlation coefficients were
computed for the maximum fall in FEV1 after EVH versus
the severity of reported respiratory symptoms. For Part 2,
paired t-tests, Wilcoxon tests, and Pearson (or Spearman)
correlation tests were conducted to evaluate the effect of the
treatment on post-EVH maximum fall in FEV1 and respira-
tory symptom scores. Statistical analyses were performed
using SPSS 18.02 for Windows (SPSS, Chicago, IL). The
level of significance was set at P G 0.05.
RESULTS
Part 1
Participants. Ninety-three participants were initially
recruited for the study; five declined to participate and one
was excluded based on anphylaxis (Fig. 1). One participant
had an underlying diagnosis of Crohn disease; however, at
the time of the study, he was asymptomatic and was not
undergoing treatment for this condition. An EVH test was
therefore carried out on 87 athletes. Of the 87 EVH tests, 85
were judged technically acceptable and were subsequently
analyzed. The two participants who were excluded did not
reach the minimum required ventilation threshold (i.e., 60%
predicted MVV) owing to a gag reflex or severe cough (the
latter leading to early termination of the test).
Baseline demographics and clinical and training character-
istics of the 85 participants are presented in Table 1. All but six
of the participants were regular competitors; 66 took part in
local sporting events and 13 competed in national and/or in-
ternational events. Forty-two participants trained in endurance-
based sports (running, 21; rowing, 12; cycling, 6; and triathlon,
3), 30 in team sports (football, 13; rugby, 9; netball, 4; hockey,
3; and cricket, 1), 10 in athletics (sprinting, 8; middle-distance
running, 1; and throwing, 1), 2 in racquet sports (squash, 1;
and tennis, 1) and one in combat sport (Thai boxing).
All 85 participants reported current respiratory symptoms
with exercise. Sixty-six (78%) had a previous medical di-
agnosis of asthma and/or EIB; in 44 of these (56%), the
diagnosis was made during childhood. In participants with-
out childhood asthma or EIB, the mean T SD age of onset
of respiratory symptoms was 25 T 9 yr. At the time of the
study, 22 athletes were prescribed salbutamol alone and 22
were prescribed inhaled corticosteroids alongside inhaled
beta2 agonist(s). Six athletes were under fixed combination
therapy (including one who was prescribed a leukotriene
receptor antagonist as add-on therapy). No significant dif-
ferences were noticed between athletes positive or negative
for EVH for anthropometric and training characteristics.
Pulmonary function in EVH-positive athletes versus
EVH-negative athletes. Forty-five athletes (53%) had a
10% or greater fall in FEV1 after EVH. The maximal fall in
FEV1 in EVH-positive athletes ranged from 10% to 50%,
with the fall in FEV1 significantly greater compared to the
EVH-negative group (P G 0.001; Table 2). In seven (15%) of
the athletes classified EVH-positive, the fall in FEV1 was
only transient (i.e., sustained for G5 min). During the EVH
test, the participants reached a mean T SD ventilation of 101 T
21 LIminj1, corresponding to 75% T 8% of predicted MVV.
The level of ventilation reached by the EVH-positive partic-
ipants did not differ significantly to the level reached by those
EVH-negative (Table 2).
Baseline spirometry revealed significant between-group
differences, with lower FEV1/FVC ($, 4.5%; 95% confi-
dence interval [CI], 1.4% to 7.7%; P = 0.006), absolute
forced expiratory flow between 25% and 75% of FVC
(FEF25–75) ($, 0.42 LIs
j1; 95% CI, 0.18 to 0.83 LIsj1; P =
0.041) and % predicted FEF25–75 ($, 11.3%; 95% CI, 3.1%
to 19.5%; P = 0.008) in the EVH-positive group. Analysis of
categorical variables revealed that women were less repre-
sented in the EVH-positive group (W2(1) = 4.95; P = 0.030),
whereas athletes with a previous medical diagnosis of asthma
and/or EIB (W2(1) = 6.96; P = 0.010), those with childhood
asthma and/or EIB (W2(1) = 6.16; P = 0.017), and those pre-
scribed inhaled corticosteroids plus beta2 agonists (W2(1) =
4.66; P = 0.046) were more represented in the EVH-positive
group (Table 1).
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Correlation analysis revealed that baseline percent pre-
dicted FEV1, PEF, and FEF25–75 values were weakly as-
sociated with the maximal % fall in FEV1 after EVH:
rs = j0.22, P = 0.039; rs = j0.24, P = 0.027; and rs =
j0.40; P G 0.001, respectively.
Respiratory symptoms in EVH-positive athletes
versus EVH-negative athletes. Wheeze was the only
symptom that significantly differed between the groups,
with the EVH-positive athletes rating significantly higher
scores than the EVH-negative athletes (P G 0.001; Table 2).
When symptom scores were pooled, the total score was
significantly greater in the EVH-positive athletes (P = 0.015;
Table 2). Moderate positive correlations were noted between
the maximum fall in FEV1 after EVH and wheeze (rs = 0.51;
P G 0.001) and total symptom scores (rs = 0.32; P = 0.003).
Cough, chest tightness, and mucus secretion were not sig-
nificantly related to the maximum fall in FEV1 after EVH.
A weak negative correlation was noted between baseline %
predicted FEF25–75 and the rating of wheeze after EVH (rs =
j0.24; P = 0.027). No other significant correlation was
found between baseline pulmonary function parameters and
symptoms scores.
Part 2
Participants. Of the 45 participants eligible for Part 2,
11 (24%) declined to return (Fig. 1). Two athletes with a
borderline response to EVH (i.e., 8%–9% fall in FEV1 after
EVH) were invited to return for Part 2. In total, therefore,
36 athletes were randomized. Athletes who returned did not
differ significantly from those who did not return for: base-
line demographics, clinical and training characteristics, air-
way response to EVH, and reported respiratory symptoms
after EVH (data not shown). Except for one of the ‘‘bor-
derline’’ participants, who felt ill after EVH in the terbuta-
line condition, all other randomized participants completed
the two arms of the study.
Effect of terbutaline on pulmonary function in
EVH-positive athletes. At rest, terbutaline had a signifi-
cant bronchodilator effect, inducing an increase in FEV1 of
FIGURE 1—Flow diagram of the progress through the two parts of the study.
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194 mL (95% CI, 149–240 mL; P G 0.001) or 5% (95% CI,
4%–6%). No such bronchodilator effect was noticed after
administration of the placebo: $FEV1 was j7 mL (95% CI,
j40 to 27 mL; P = 0.695) or 0% (95% CI, j1% to 1%).
During the EVH test, ventilation was slightly ($,1.3 LIminj1;
95% CI, 0.3–2.4 LIminj1), but significantly (P = 0.015), in-
creased in the terbutaline condition (Table 3).
In the placebo condition, all but one athlete had a 10% or
greater fall in FEV1 after EVH, with the peak fall in FEV1
occurring within the first 15 min of recovery in all partici-
pants. The only athlete with a negative response had an
8% fall, which was close to the 10% fall noted for that par-
ticipant in Part 1. Terbutaline inhibited hyperpnea-induced
bronchoconstriction in 83% of athletes, with a mean degree of
bronchoprotection of 53% (95% CI, 45%–62%). The six
athletes who remained positive to EVH in the terbutaline
condition had a maximum fall in FEV1 of 16% (95% CI,
11%–21%). Overall, the maximum fall in FEV1 after EVH
was significantly reduced in the terbutaline condition (P G
0.001; Table 3). There was no significant correlation between
the maximum fall in FEV1 and the level of ventilation
achieved by athletes during the EVH test in either the placebo
or the terbutaline condition (P 9 0.05).
Association between pulmonary function values
and respiratory symptoms after induced and
inhibited bronchoconstriction in EVH-positive
athletes. Although terbutaline reduced group mean symp-
tom scores (Table 3), the degree of bronchoprotection
afforded by terbutaline did not correlate with individual
differences in symptom scores between the terbutaline and
placebo conditions (Fig. 2A–D). Furthermore, of the 29
athletes who had less than 10% fall in FEV1 after EVH, 14
(48%) rated at least one respiratory symptom higher in the
terbutaline condition (Fig. 3A–D). Finally, more than one
quarter of these athletes (28%) had a higher total symptom
score under terbutaline.
DISCUSSION
Respiratory symptoms are often the basis for the diagno-
sis and treatment of EIB. Our data suggest that group mean
scores for perceived respiratory symptoms (including cough,
wheeze, chest tightness, and mucus secretion) are reduced
when hyperpnea-induced bronchoconstriction is at least
partly inhibited by prophylactic administration of the bron-
chodilator agent terbutaline in symptomatic athletes with
TABLE 1. Baseline demographics and clinical and training characteristics of the participants.
All (n = 85) EVHj (n = 40) EVH+ (n = 45)
Age, yr 26 T 9 26 T 9 26 T 10
Sex (females) 36 (42%) 22 (55%) 14 (31%)*
Height, cm 174 T 8 173 T 9 176 T 8
Body mass, kg 74.6 T 13.6 73.4 T 14.8 75.7 T 12.5
Medical diagnosis of asthma/EIB 66 (78%) 26 (65%) 40 (89%)*
Childhood asthma/EIB 44 (52%) 15 (38%) 29 (64%)*
Family asthma 45 (53%) 18 (45%) 27 (60%)
SABA only 22 (26%) 8 (20%) 14 (31%)
SABA + ICS 22 (26%) 6 (15%) 16 (36%)*
Reported allergies 53 (62%) 24 (60%) 29 (64%)
FVC, L 4.89 T 0.99 4.72 T 0.98 5.04 T 0.98
FVC, % pred. 106 T 11 106 T 12 106 T 10
FEV1, L 3.87 T 0.71 3.86 T 0.73 3.88 T 0.70
FEV1, % pred. 99 T 11 102 T 10 97 T 11
FEV1/FVC, % 80 T 8 82 T 6 78 T 9**
FEF25–75, LIs
j1 3.65 T 0.96 3.88 T 0.87 3.46 T 1.00*
FEF25–75, % pred. 81 T 20 87 T 15 76 T 23**
PEF, LIsj1 8.41 T 1.56 8.38 T 1.76 8.44 T 1.38
PEF, % pred. 96 T 13 99 T 15 94 T 10
Training, hIwkj1 9 T 6 11 T 7 8 T 4
Training, yr 8 T 6 8 T 5 9 T 6
Values are presented as mean T SD (or n [%]).
*P G 0.05, **P G 0.01 indicate significantly different from EVHj.
EVHj, athletes with less than 10% fall in FEV1 after EVH of dry air; EVH
+, athletes with 10% or greater fall in FEV1 after EVH of dry air; FEV1, forced expiratory volume in 1 sec; FEF25–75,
forced expiratory flow between 25% and 75% of FVC; FVC, forced vital capacity; ICS, inhaled corticosteroid; PEF, peak expiratory flow; SABA, inhaled short-acting beta2 agonist; % pred.,
% of predicted value (27).
TABLE 2. Airway response and self-reported respiratory symptoms after 8 min of EVH of dry air in symptomatic athletes positive (EVH+) or negative (EVHj) for exercise-induced
bronchoconstriction (EIB).
EVHj (n = 40) EVH+ (n = 45) Difference: EVH+ j EVHj (95% CI)
Achieved V˙E, LIminj1 99 T 21 103 T 20 3 (j6 to 12)
Achieved V˙E, % pred. MVV 74 T 8 76 T 8 2 (j1 to 5)
Max fall in FEV1 after EVH, % 6 T 2 19 T 11*** 13 (10 to 17)
Cough, cm 5.8 T 2.7 5.9 T 2.2 0.0 (j1.0 to 1.1)
Wheeze, cm 3.5 T 2.5 6.4 T 1.6*** 2.9 (2.0 to 3.8)
Chest tightness, cm 4.1 T 2.5 5.0 T 2.6 0.8 (j0.3 to 1.9)
Mucus secretion, cm 5.3 T 2.7 5.0 T 2.6 j0.3 (j1.4 to 0.9)
Total symptoms score, cm 18.8 T 6.9 22.2 T 5.9* 3.4 (0.7 to 6.2)
Values are presented as mean T SD (or 95% CI).
*P G 0.05 and ***P G 0.001 indicate significantly different from EVHj.
V˙E, minute ventilation; % pred. MVV, percentage of predicted maximal voluntary ventilation.
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EIB. However, at an individual level, perception scores for
respiratory symptoms did not correlate with the changes
in airway caliber induced by dry air hyperpnea with and
without premedication with 0.5 mg of inhaled terbutaline.
Wheeze during EVH challenge was the only respiratory
symptom (of the four tested) that differentiated athletes
positive compared to those negative to EVH (with higher
scores reported by EVH-positive athletes). Therefore, there
is a caveat in systematically prescribing inhaled beta2 ago-
nists to athletes reporting respiratory symptoms on exertion
and in relying on self-reported symptoms to assess the effi-
cacy of bronchodilator treatment for EIB prevention.
The novelty of this work resides in the conjoint assess-
ment of a change in airway caliber (measured by FEV1) and
in subjective ratings of respiratory symptoms in a condition
of induced bronchoconstriction versus a condition of at least
partly inhibited bronchoconstriction in athletes with EIB. In
the past, the link between self-reported respiratory symptoms
and airway caliber has only ever been assessed in athletes
after induced bronchoconstriction, using either exercise
(31,32,36) or its surrogates, e.g., EVH (7,17,36) or man-
nitol (36). These studies have consistently shown respira-
tory symptoms to be poor predictors of EIB. In our group of
athletes, all of whom reported respiratory symptoms on
TABLE 3. Airway response and reported respiratory symptoms after 8 min of EVH of dry air in symptomatic athletes with EIB premedicated with either 0.5 mg of terbutaline or a placebo.
Placebo (n = 35) Terbutaline (n = 35) Difference: Terbutaline – Placebo (95% CI)
Achieved V˙E, LIminj1 104 T 21 105 T 21* 1.3 (0.3 to 2.4)
Achieved V˙E, % pred. MVV 80 T 7 82 T 8** 2.2 (0.8 to 3.6)
Max fall in FEV1 after EVH, % 16 T 7 7 T 5*** j8.8 (j6.1 to j11.4)
Cough, cm 5.5 T 2.0 3.9 T 2.7** j1.7 (j0.8 to j2.6)
Wheeze, cm 5.4 T 2.1 4.2 T 2.2** j1.2 (j0.5 to j2.0)
Chest tightness, cm 5.1 T 2.2 3.8 T 2.7** j1.3 (j0.5 to j2.1)
Mucus secretion, cm 5.0 T 2.5 3.9 T 2.5** j1.1 (j0.4 to j1.8)
Total symptoms score, cm 21.1 T 7.4 15.8 T 8.3*** j5.3 (j2.8 to j7.8)
Values are presented as mean T SD (or 95% CI).
*P G 0.05, **P G 0.01, and ***P G 0.001 indicate significantly different from placebo.
FIGURE 2—Absence of correlation between the change in respiratory symptoms (A, wheeze; B, mucus secretion; C, chest tightness; D, cough) and the
degree of bronchoprotection afforded by terbutaline after EVH of dry air in 35 symptomatic athletes with EIB. Zero percent bronchoprotection:
similar fall in FEV1 after EVH with terbutaline and placebo; 100% bronchoprotection: no fall in FEV1 after EVH with terbutaline; delta values were
calculated as the difference between symptom scores under terbutaline minus symptom scores under placebo (with a negative delta value indicating an
improved respiratory symptom score under terbutaline).
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exertion, only approximately half was positive for EIB
when diagnosis with pulmonary function testing using a
bronchial provocation challenge with dry air was used
(53% if a 10% threshold in FEV1 fall post-EVH was used
and 45% if a sustained FEV1 fall was considered). Al-
though prophylactic administration of terbutaline reduced
group mean respiratory symptoms scores after EVH, the
difference in symptom scores between the active drug
and placebo conditions did not correlate with the degree of
bronchoprotection afforded by terbutaline. Furthermore, of
the athletes with less than 10% fall in FEV1 after EVH after
inhalation of terbutaline, almost half rated at least one re-
spiratory symptom higher compared to placebo (i.e., when
significant bronchoconstriction occurred). This highlights
a disconnection between objective changes of airway cali-
ber and self-report of respiratory symptoms in athletes, and
confirms our secondary hypothesis that symptoms alone
cannot be used to identify or exclude the presence of bron-
choconstriction in athletes.
In the current study, the only symptom that significantly
differed between EVH-positive and EVH-negative and that
positively correlated with the maximum fall in FEV1 after
EVH was wheeze. This somewhat contradicts the findings
of Rundell et al. (31), which showed no association between
the reporting of wheeze during usual training and the bron-
chial response to a sport/environment-specific field exercise
challenge test. However, the same authors (32) found, in a
different athletic population (i.e., elite women ice hockey
players), that the presence of cough (not wheeze, chest
tightness, or excess mucus) was significantly related to EIB
(when EIB was assessed through a skating challenge in cold/
dry air). Furthermore, using EVH as a surrogate for exercise,
Holzer et al. (17) found in elite summer-sport athletes that
wheeze had one of the highest positive predictive values for
EIB (71%). More recently, Couillard et al. (11) showed that
airway hyper-responsiveness to EVH and/or methacholine
was associated with an increased perception of wheeze after
EVH in competitive athletes (endurance athletes, swimmers,
and winter athletes). Together, these results suggest that no
single respiratory symptom can be used to accurately detect
EIB in athletes, and that the mode of bronchoprovocation
as well as the choice of the study population may influence
the relationship between self-reported symptoms and the se-
verity of induced bronchoconstriction.
The reporting of respiratory symptoms during and/or
shortly after exercise, independent of airway narrowing, is
not specific to athletic populations. Symptoms that mimic
EIB have been reported in patients with exercise-induced
dyspnea in the absence of bronchoconstriction when exer-
cise was performed in the cold (37). Cold air and dry air are
known to directly trigger cough and glandular secretion
through sensory C-fibers (15) and submucosal gland cell
FIGURE 3—Individual ratings of respiratory symptoms (A, wheeze; B, mucus secretion; C, chest tightness; D, cough) after treatment with 0.5 mg
terbutaline or placebo in 29 symptomatic athletes positive to EVH under placebo but negative under terbutaline. Closed circles represent athletes who
scored symptoms higher under terbutaline (A, n = 9; B, n = 8; C, n = 7; D, n = 7).
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activation (14), respectively. The large thermal and osmotic
stress placed upon the airways during exercise or dry air
hyperpnea (as used in the current study) may therefore ex-
plain the frequent reporting of cough and mucus hyper-
secretion by athletes.
Exercise may also initiate a cough reflex and mucus
hypersecretion indirectly, i.e., via an inflammatory response
and/or injury to the airway epithelium. Hyperpnea of dry air
has been shown to cause release of the inflammatory medi-
ator prostaglandins, both in athletes with EIB and those
without EIB (19). The excitability of nociceptive C-fiber
afferents in the lungs increases in the presence of inflam-
matory mediators, such as prostaglandins and leukotrienes
(20,25). Furthermore, acute exercise (5,10) and dry air hy-
perpnea (6,33) have been shown to perturb the integrity of
the airway epithelium. Injury to the airway epithelium would
expose sensory nerve endings to noxious agents (such as air
pollutants and allergens) and may trigger a neurogenic in-
flammation (28). In swimmers (7), runners (29), and ice-
arena athletes (32)—all of whom are frequently exposed to
noxious airborne agents (e.g., chlorine derivatives and ex-
haust gas from cars or from fossil-fueled ice-resurfacing
machines)—high prevalence of respiratory symptoms and
pulmonary dysfunction has consistently been reported. That
hyperpnea of dry air may stimulate cough and mucus
hypersecretion independently of a change in airway caliber
may explain why wheeze, which is more directly linked to
airflow limitation (34), differentiated better EVH-positive
athletes from EVH-negative athletes in Part 1 of this study.
Our intervention was highly successful in that inhalation
of the single therapeutic dose of 0.5 mg of terbutaline
inhibited bronchoconstriction (i.e., G10% fall in FEV1 after
EVH) in 83% of the athletes. Whereas many reports have
focused solely on the link between self-report of respiratory
symptoms by athletes and airway response to broncho-
provocation (7,11,17,31,32,36), the inclusion of a terbuta-
line arm in our study design provides novel practical
information for physicians; that is, changes in self-reported
respiratory symptoms after prophylactic usage of inhaled
beta2 agonists before exercise should not be relied on for the
detection and management of EIB in athletes. However, it
should be acknowledged that the prophylactic effect of ter-
butaline on self-reported respiratory symptoms was only
assessed on a single occasion. Yet, in daily practice, health
care providers may give athletes several weeks to assess
whether the medication has any perceived benefits.
Owing to its high sensitivity (13,30), EVH of dry air is the
recommended bronchial provocation test for EIB diagnosis in
elite athletes (2). Therefore, EVH was preferred to exercise
challenge in the current study. One potential limitation,
however, is that we were not in a position to assess the origin
of the respiratory symptoms in the group of athletes negative
to EVH. Recent evidence suggests that exercise-induced la-
ryngeal obstruction is a common differential diagnosis in
symptomatic athletes (24). Alternative causes for unexplained
respiratory symptoms in athletes include rhinitis, recurrent
upper respiratory tract infection, gastroesophageal reflux
disease, and hyperventilation syndrome (8).
CONCLUSION
Our aim was to further characterize the subjective per-
ception of bronchoconstriction in athletes. In Part 1, we
compared post-EVH reports of respiratory symptoms in
athletes positive and negative for EIB. In Part 2, we used a
novel study design in which athletes with EIB were
premedicated with either a bronchodilator (i.e., 0.5 mg ter-
butaline) or a placebo ahead of a bronchial provocation test
with dry air. Of the four symptoms commonly associated
with EIB (i.e., cough, wheeze, chest tightness, and mucus
secretion), wheeze was the only one that significantly dif-
fered after dry air challenge between athletes positive to
EVH and those negative to EVH. Furthermore, there was
no evidence of a relationship between the degree of
bronchoprotection afforded by terbutaline and differences in
respiratory symptom scores between the terbutaline and
placebo conditions. Therefore, health care providers should
not rely solely on changes in subjective ratings of respiratory
symptoms after prescription of inhaled beta2 agonists when
posing a diagnosis of EIB in athletes. This reinforces the
need for objective evidence of EIB for effective diagnosis
and management of EIB in athletes (17,31).
The World Anti-Doping Agency (WADA) provided funding for this
work, which made data collection possible.
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